IFIT1 and neoplasm: Mimicking the depleted human pro-tumor TAN subtypes (Neu_09_IFIT1, Neu_10_SPP1, and Neu_11_CCL4) selectively by using an anti-ly6G antibody in a mouse model of liver cancer, the study found that the anti-tumor mouse Neu_09_Apoa2 subtype (corresponding to human Neu_07_APOA2) expanded within tumors, macrophage recruitment was hindered and T cell was suppressed, thereby restraining tumor progression.42